Prostate CancerProDecANCT03278197
Evaluation of a Web-based Decision Aid Tool for Prostate Cancer Patients
A study testing Interviews, Treatmentchoice Decisional Tool and Questionnaires in people with Prostate Cancer, run by Maastricht Radiation Oncology at 1 site in Netherlands.
Trial summary
Patients diagnosed with localized prostate cancer may be eligible for different treatment options. MAASTRO Clinic (MAAStricht Radiation Oncology) developed a web-based decision aid tool for these patients. Read more about this study
- Who is it for?
- Ages 18 years and older, men onlyHealthy volunteers can take part
- Conditions the study is for
- Prostate Cancer
- What is being tested?
- Interviews, Treatmentchoice Decisional Tool and Questionnaires
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 11 participants
- Where
- 1 siteNetherlands
- Study dates
- Jan 2015to Feb 2017
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- Men only
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- Stage I-II primary prostate cancer
- Proficient in Dutch
- > 18 years old
Who cannot join
- Patients that do not have a treatment choice (due to contra-indications or other medical reasons)
- Patients with recurrent disease.
- For alpha testing patients that already made their decision are selected. For each treatment (external beam radiotherapy (RT), interstitial RT, surgery and active surveillance) at least 10 patients will be included.
- For beta testing patients that are facing their decision will be included. Aiming for an effect size of 0.60 for a difference in mean total score on the Decisional Conflict Scale, it would require 45 patients per group (pre and post intervention) to determine this effect with alpha 0.05 and power 0.80.
- For the Delphi study prostate cancer patients who already underwent treatment will be included.
- Clinicians:
Show all 13Show fewer
- Radiotherapy-oncologists
- Urologists
- General practitioners
- Nurses.
- For alpha testing at least 10 physicians are selected.
- For beta testing at least 45 questionnaires are required.
- Patient organizations and insurance companies will be interviewed to evaluate barriers and facilitators for implementation in clinical practice. The study will focus on their respective roles in the promotion of shared decision making: patient organizations in raising awareness among patients and insurance companies in providing incentives for the use of decision aids in clinical practice.
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Evaluating a Decision Aid in Clinical Practice for Patients With Localized Prostate Cancer
Patients diagnosed with localized prostate cancer may be eligible for different treatment options. MAASTRO Clinic (MAAStricht Radiation Oncology) developed a web-based decision aid tool for these patients. The goal of the tool is to help patients to understand the treatments, and empower the patients to participate in the decision making process. The aim of this study is threefold:
(A) user-testing and validation of the tool, by using a systematically development process compliant with the IPDAS (International Patients Decision Aids Standards) criteria (B) establish the impact of the tool on the decision making process; (C) identify barriers and facilitators for the implementation of shared decision making and the tool in clinical practice.
Read more
The study covers 3 phases:
- Development phase 1.1 Assess decisional needs of patients and clinicians. 1.2 Test patients' and clinicians' comprehensibility, acceptability and usability on the alpha-version of the tool. 1.3 Value clarification: Delphi study with former prostate cancer patients to determine the most important patient preferences and value clarification aspects the decision aid should include.
- Implementation phase: Develop an implementation and dissemination plan for shared decision-making which is based on the evaluation of barriers and facilitators for the use of patient decision aid tools in clinical practice.
- Evaluation phase: Establish the impact of on knowledge, decisional conflict and the shared decision-making process, as well as the extent to which clinicians involve patients in decision-making.
A mixed method will be used. It comprises structured interviews combined with think aloud and questionnaires with stakeholders involved in the whole process of development, implementation and evaluation (patients, urologists, radiotherapists, nurses, general practitioners, patient organizations, and insurance companies).
Read the detailed description
Prostate cancer is the most common malignancy observed among men in industrialized countries, with 1.11 million new cases diagnosed in 2012 . For patients with localized prostate cancer, different treatment options are available; radical prostatectomy, external beam radiotherapy, interstitial radiotherapy also called Brachytherapy (early-stage disease), and 'active surveillance' (low risk patients). The optimal treatment for patients having localized prostate cancer is not unambiguously proven. Different treatment options cause different side effects that may impact the patients' health-related quality of life. The treatment of choice depends on preferences and personal values. In these preference-sensitive choices it is important to involve the patient in the decision-making process. In this process both the practitioner and the patient exchange information and collaborate in the decision, the physician knows more technical information about the disease, the treatment options and the side effects, the patient knows how the treatment options correspond with his lifestyle, values and preferences.
Patient Decision Aids (PDAs) are tools that can help patients to get involved in decision making by clarifying treatment options, outcomes, and personal values. In the development process of a decision aid it is mandatory to follow a systematic and iterative approach to: (a) understand patient's decisional needs; (b) create prototypical tools; (c) evaluate these prototypes with patients and clinicians, and (d) use these results to improve the tool.
Considering the International Patient Decision Aid Standards (http://ipdas.ohri.ca/), the investigators designed an initial prototype, called Treatmentchoice (http://www.treatmentchoice.info). These standards recommend assessing patients and doctors views in decisional needs, use this information to develop an alpha version of the PDA and validate the Treatmentchoice again with patients and doctors to create a beta version.
The aim of this project is user-testing the initial prototype of the Treatmentchoice. This will allow the investigators to follow a systematic development process and to gain knowledge on the validity of approach of the investigators. The project covers 4 activities:
ACTIVITY 1.1: ASSESS DECISIONAL NEEDS: Elicit patients' and clinicians' views on patient's information, expectations, and needs on decision support. Conclusions and recommendations for improvement of Treatmentchoice will be derived and the current prototype will be improved creating an alpha prototype.
ACTIVITY 1.2: ALPHA-TESTING: Testing patients' and clinicians' comprehensibility, acceptability and usability on the alpha prototype. A mixed method will be used; structured interviews combined with think aloud (Ahmed, 2009) and questionnaires (Unified Theory of Acceptance and Use of Technology (UTAUT) - Venkatesh et al.) with both patients and clinicians (urologists, radiotherapists and general practitioners). Conclusions and recommendations will be documented. Considering this assessment, the prototype will be improved. Alpha testing will be repeated with this improved prototype using an iterative process, until the tool is comprehensible, acceptable and usable for both patients and physicians.
ACTIVITY 1.3: DELPHI STUDY: Gain an in-depth understanding of the information needs of prostate cancer patients at each stage from diagnosis to treatment and post-treatment. The purpose is to improve the contents of the decision aid so that it contains an accurate representation of the factors that are most relevant to prostate cancer patients. First, focus group interviews with former prostate cancer patients and patient organizations will be carried out. The results will be analyzed and a list of factors will be generated. A Delphi consensus process will be used to rank the relative importance of these factors and the tool will be updated to give information that is most important for patients.
ACTIVITY 2: IMPACT STUDY (or beta testing): Evaluation of the impact of Treatmentchoice on knowledge, decisional conflict and the shared decision making process, as well as the extent to which clinicians involve patients in decision making. A variety of questionnaires will be used to assess different outcome measures:
- Age and educational level, home internet connection, and computer skills
- Knowledge test will be assessed using 20 statements, which can be rated as "true", "false" or "do not know" .
- Decisional conflict will be assessed using the Decisional Conflict Scale (DCS). This 16-item scale has five subscales: feeling informed, decisional uncertainty, clear values, support, and quality of decisions. Each of these items is scored on a five-point Likert scale from 1 (strongly agree) to 5 (strongly disagree).
- Patient's desire to participate in medical decisions will be assessed using a 5-item Control Preference Scale.
- The Shared Decision Making (SDM) process will be assessed by the perceptions of patients, using the SDM-Q9 instrument for patients. The instrument provides 9 statements, which can be rated on a six-point scale from 0 (completely disagree) to 5 (completely agree). (SDM-Q9, Rodenburg, 2015 /Dutch version).
- The process of SDM will also be assessed by the perceptions of the physician (the urologist or the RTO if the decision is made together with an RTO), using the SDM-Q9 instrument for professionals. The instrument provides 9 statements, also rated on a six-point scale.
The patients will be asked to fill in the questionnaires at two time points: directly after the decision making process and 3 months after the decision making process. Their physician will be asked to fill in the questionnaire at one-time point, directly after the decision making process.
ACTIVITY 3: IMPLEMENTATION: Identify key aspects on the implementation and dissemination for shared decision-making in prostate cancer. Semi-structured interviews will be performed to recognize barriers and facilitators for implementation in clinical practice, to develop strategies for the implementation of decision aids and to facilitate optimal shared decision-making which is tailored to the needs of the end-users (patients and doctors).
- Conditions
- Prostate Cancer
- Being tested
- Interviews, Treatmentchoice Decisional Tool, Questionnaires, Interviews with stakeholders
- Medical subject headings
- Prostatic Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
InterviewsOther
Interviews with patients, physicians and general practitioners (GPs) to define patients' decisional needs.
Treatmentchoice Decisional ToolOther
Patients and physicians navigate through Treatmentchoice Decisional Tool and think aloud while running the tool
QuestionnairesOther
Patients and physicians fill out questionnaires on the usual care, Delphi study
Interviews with stakeholdersOther
Interviews with stakeholders (patients, clinicians, nurses, GP's, patient organizations, insurance companies) to determine the barriers and facilitators to the implementation of shared decision making and the decision aid.
| Study group | Role | What they receive |
|---|---|---|
| 1.Patients | Experimental | Patients diagnosed with prostate cancer and ex-prostate cancer patients:
* Interviews with patients to define their decisional needs and to determine the barriers and facilitators to the implementation of shared decision making and the decision aid.
* Navigating through the Treatmentchoice Decisional Tool and think aloud while running the tool
* Questionnaires Receives: Other: Interviews; Other: Treatmentchoice Decisional Tool; Other: Questionnaires |
| 2.Clinicians | Other | Radiotherapy-oncologists, Urologists, General practitioners, Nurses
* Interviews with patients to define their decisional needs and to determine the barriers and facilitators to the implementation of shared decision making and the decision aid.
* Navigating through the Treatmentchoice Decisional Tool and think aloud while running the tool
* Questionnaires Receives: Other: Interviews; Other: Treatmentchoice Decisional Tool; Other: Questionnaires |
| 3.Other involved organizations | Other | Patient Organizations and insurance companies Interviews with stakeholders (patients, clinicians, nurses, GP's, patient organizations, insurance companies) to determine the barriers and facilitators to the implementation of shared decision making and the decision aid Receives: Other: Interviews with stakeholders |
What is being measured
The primary outcome is the main question the study is designed to answer.
Patient's decisional needs to make a decision about their treatment
Patients' decisional needs (development phase):semi-structured interviews with patients about their medical history, their experience with the treatment, the decision about their treatment, and what information the patients need to make an informed decision
Measured: up to 1 year
Comprehensibility of the decision aid too
Quantitative research using the Unified Theory of Acceptance and Use of Technology (UTAUT Venkatesh et al. 2013). This questionnaire. (5-Likert) measure how patients and clinicians perceived its utility, effectiveness and efficiency for shared decision-making, as well as their satisfaction with the decision aid.
Measured: up to 1 year
Usability of the decision aid too
Quantitative research using a questionnaire based on the International Standard ISO-9242-11. This questionnaire (5-Likert) measure to what extent the decision aid is easy to use.
Measured: up to 1 year
Decisional conflict (patients, evaluation phase)
Decisional conflict will be assessed using the DCS (Decisional conflict scale): change in DCS between baseline group (usual care) and intervention group (use of the aid tool)
Measured: 2 weeks after diagnosis
Control Preference Scale (patients; evaluation phase)
Patient's preference to participate in medical decisions will be assessed using the 5-item Control Preference Scale (CPS):change in CPS between baseline group (usual care) and intervention group (use of the aid tool)
Measured: 2 weeks after diagnosis
Perception shared decision-making (patients; evaluation phase)
Patient's perception of the shared decision-making process will be assessed using the (shared decision making) SDM-Q9 instrument for patients: change in SDM between baseline group (usual care) and the intervention group (use of the aid tool)
Measured: 2 weeks after diagnosis
Perception shared decision-making (doctors; evaluation phase)
Doctor's perception of the shared decision-making process will be assessed using the SDM-Q9 instrument for professionals: change in SDM between baseline group (usual care) and the intervention group (use of the aid tool)]]
Measured: 2 weeks after diagnosis
Secondary outcomes (4)
Patients' views on the current decision-making process
Patients' views on the current decision-making process (development phase)
Measured: upto 1 year
Patients' satisfaction with decision aid (Treatmentchoice)
Patients' satisfaction with decision aid (Treatmentchoice) (development phase)
Measured: upto 1 year
Patients' intention to use and recommend Treatmentchoice to others
Patients' intention to use and recommend Treatmentchoice to others (development phase)
Measured: upto 1 year
Insights into the value clarification process of prostate cancer patients
Insights into the value clarification process of prostate cancer patients by questionnaires (development phase)
Measured: an average of 2 year
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted11 Sep 2017
- Study startJan 2015
- Primary completionFeb 2016
- Study completionFeb 2017
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Prostate CancerStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Supportive care
- Allocation
- Non-randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 11 participants (actual)
Sponsor and investigators
- Lead sponsor
- Maastricht Radiation Oncology
- Sponsor type
- University, hospital or other
- Collaborators
- Maastricht University Medical Center, Zuyderland Medical Centre, VieCuri Medical Centre, Laurentius Ziekenhuis Roermond, St.Jans Gasthuis Weert
- Responsible party
- Sponsor
- Investigators
- Philippe Lambin, MD,PhD, Principal investigator, Maastro Clinic, The Netherlands
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03278197
- Sponsor's protocol ID
- 14-40-19/11-intern-6745
- Acronym
- ProDecA
- Status last verified
- Nov 2020
- First submitted
- 22 Feb 2017
- Last updated
- 30 Nov 2020
- Results posted
- No
- Data monitoring committee
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 30 Nov 2020. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Evaluating a Decision Aid in Clinical Practice for Patients With Localized Prostate Cancer
- ClinicalTrials.gov ID
- NCT03278197
- Acronym / sponsor ID
- ProDecA / 14-40-19/11-intern-6745
- Conditions
- Prostate Cancer
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 11 participants (actual)
- Lead sponsor
- Maastricht Radiation OncologyUniversity, hospital or other
- Collaborators
- Maastricht University Medical Center, Zuyderland Medical Centre, VieCuri Medical Centre, Laurentius Ziekenhuis Roermond, St.Jans Gasthuis Weert
- Study start
- Jan 2015 (actual)
- Primary completion
- Feb 2016 (actual)
- Study completion
- Feb 2017 (actual)
- First posted
- 11 Sep 2017 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Patients diagnosed with localized prostate cancer may be eligible for different treatment options. MAASTRO Clinic (MAAStricht Radiation Oncology) developed a web-based decision aid tool for these patients. The goal of the tool is to help patients to understand the treatments, and empower the patients to participate in the decision making process. The aim of this study is threefold:
(A) user-testing and validation of the tool, by using a systematically development process compliant with the IPDAS (International Patients Decision Aids Standards) criteria (B) establish the impact of the tool on the decision making process; (C) identify barriers and facilitators for the implementation of shared decision making and the tool in clinical practice.
The study covers 3 phases:
- Development phase 1.1 Assess decisional needs of patients and clinicians. 1.2 Test patients' and clinicians' comprehensibility, acceptability and usability on the alpha-version of the tool. 1.3 Value clarification: Delphi study with former prostate cancer patients to determine the most important patient preferences and value clarification aspects the decision aid should include.
- Implementation phase: Develop an implementation and dissemination plan for shared decision-making which is based on the evaluation of barriers and facilitators for the use of patient decision aid tools in clinical practice.
- Evaluation phase: Establish the impact of on knowledge, decisional conflict and the shared decision-making process, as well as the extent to which clinicians involve patients in decision-making.
A mixed method will be used. It comprises structured interviews combined with think aloud and questionnaires with stakeholders involved in the whole process of development, implementation and evaluation (patients, urologists, radiotherapists, nurses, general practitioners, patient organizations, and insurance companies).
Detailed description
Prostate cancer is the most common malignancy observed among men in industrialized countries, with 1.11 million new cases diagnosed in 2012 . For patients with localized prostate cancer, different treatment options are available; radical prostatectomy, external beam radiotherapy, interstitial radiotherapy also called Brachytherapy (early-stage disease), and 'active surveillance' (low risk patients). The optimal treatment for patients having localized prostate cancer is not unambiguously proven. Different treatment options cause different side effects that may impact the patients' health-related quality of life. The treatment of choice depends on preferences and personal values. In these preference-sensitive choices it is important to involve the patient in the decision-making process. In this process both the practitioner and the patient exchange information and collaborate in the decision, the physician knows more technical information about the disease, the treatment options and the side effects, the patient knows how the treatment options correspond with his lifestyle, values and preferences.
Patient Decision Aids (PDAs) are tools that can help patients to get involved in decision making by clarifying treatment options, outcomes, and personal values. In the development process of a decision aid it is mandatory to follow a systematic and iterative approach to: (a) understand patient's decisional needs; (b) create prototypical tools; (c) evaluate these prototypes with patients and clinicians, and (d) use these results to improve the tool.
Considering the International Patient Decision Aid Standards (http://ipdas.ohri.ca/), the investigators designed an initial prototype, called Treatmentchoice (http://www.treatmentchoice.info). These standards recommend assessing patients and doctors views in decisional needs, use this information to develop an alpha version of the PDA and validate the Treatmentchoice again with patients and doctors to create a beta version.
The aim of this project is user-testing the initial prototype of the Treatmentchoice. This will allow the investigators to follow a systematic development process and to gain knowledge on the validity of approach of the investigators. The project covers 4 activities:
ACTIVITY 1.1: ASSESS DECISIONAL NEEDS: Elicit patients' and clinicians' views on patient's information, expectations, and needs on decision support. Conclusions and recommendations for improvement of Treatmentchoice will be derived and the current prototype will be improved creating an alpha prototype.
ACTIVITY 1.2: ALPHA-TESTING: Testing patients' and clinicians' comprehensibility, acceptability and usability on the alpha prototype. A mixed method will be used; structured interviews combined with think aloud (Ahmed, 2009) and questionnaires (Unified Theory of Acceptance and Use of Technology (UTAUT) - Venkatesh et al.) with both patients and clinicians (urologists, radiotherapists and general practitioners). Conclusions and recommendations will be documented. Considering this assessment, the prototype will be improved. Alpha testing will be repeated with this improved prototype using an iterative process, until the tool is comprehensible, acceptable and usable for both patients and physicians.
ACTIVITY 1.3: DELPHI STUDY: Gain an in-depth understanding of the information needs of prostate cancer patients at each stage from diagnosis to treatment and post-treatment. The purpose is to improve the contents of the decision aid so that it contains an accurate representation of the factors that are most relevant to prostate cancer patients. First, focus group interviews with former prostate cancer patients and patient organizations will be carried out. The results will be analyzed and a list of factors will be generated. A Delphi consensus process will be used to rank the relative importance of these factors and the tool will be updated to give information that is most important for patients.
ACTIVITY 2: IMPACT STUDY (or beta testing): Evaluation of the impact of Treatmentchoice on knowledge, decisional conflict and the shared decision making process, as well as the extent to which clinicians involve patients in decision making. A variety of questionnaires will be used to assess different outcome measures:
- Age and educational level, home internet connection, and computer skills
- Knowledge test will be assessed using 20 statements, which can be rated as "true", "false" or "do not know" .
- Decisional conflict will be assessed using the Decisional Conflict Scale (DCS). This 16-item scale has five subscales: feeling informed, decisional uncertainty, clear values, support, and quality of decisions. Each of these items is scored on a five-point Likert scale from 1 (strongly agree) to 5 (strongly disagree).
- Patient's desire to participate in medical decisions will be assessed using a 5-item Control Preference Scale.
- The Shared Decision Making (SDM) process will be assessed by the perceptions of patients, using the SDM-Q9 instrument for patients. The instrument provides 9 statements, which can be rated on a six-point scale from 0 (completely disagree) to 5 (completely agree). (SDM-Q9, Rodenburg, 2015 /Dutch version).
- The process of SDM will also be assessed by the perceptions of the physician (the urologist or the RTO if the decision is made together with an RTO), using the SDM-Q9 instrument for professionals. The instrument provides 9 statements, also rated on a six-point scale.
The patients will be asked to fill in the questionnaires at two time points: directly after the decision making process and 3 months after the decision making process. Their physician will be asked to fill in the questionnaire at one-time point, directly after the decision making process.
ACTIVITY 3: IMPLEMENTATION: Identify key aspects on the implementation and dissemination for shared decision-making in prostate cancer. Semi-structured interviews will be performed to recognize barriers and facilitators for implementation in clinical practice, to develop strategies for the implementation of decision aids and to facilitate optimal shared decision-making which is tailored to the needs of the end-users (patients and doctors).
Study design
- Primary purpose
- Supportive care
- Allocation
- Non-randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| 1.Patients | Experimental | Other: Interviews, Other: Treatmentchoice Decisional Tool, Other: QuestionnairesPatients diagnosed with prostate cancer and ex-prostate cancer patients: * Interviews with patients to define their decisional needs and to determine the barriers and facilitators to the implementation of shared decision making and the decision aid. * Navigating through the Treatmentchoice Decisional Tool and think aloud while running the tool * Questionnaires |
| 2.Clinicians | Other | Other: Interviews, Other: Treatmentchoice Decisional Tool, Other: QuestionnairesRadiotherapy-oncologists, Urologists, General practitioners, Nurses * Interviews with patients to define their decisional needs and to determine the barriers and facilitators to the implementation of shared decision making and the decision aid. * Navigating through the Treatmentchoice Decisional Tool and think aloud while running the tool * Questionnaires |
| 3.Other involved organizations | Other | Other: Interviews with stakeholdersPatient Organizations and insurance companies Interviews with stakeholders (patients, clinicians, nurses, GP's, patient organizations, insurance companies) to determine the barriers and facilitators to the implementation of shared decision making and the decision aid |
Who may qualify
- Ages
- 18 years and older
- Sex
- Male only
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (3 listed)
Key exclusion criteria (13 listed)
- For alpha testing patients that already made their decision are selected. For each treatment (external beam radiotherapy (RT), interstitial RT, surgery and active surveillance) at least 10 patients will be included.
- For beta testing patients that are facing their decision will be included. Aiming for an effect size of 0.60 for a difference in mean total score on the Decisional Conflict Scale, it would require 45 patients per group (pre and post intervention) to determine this effect with alpha 0.05 and power 0.80.
- For the Delphi study prostate cancer patients who already underwent treatment will be included.
- Clinicians:
- For alpha testing at least 10 physicians are selected.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| InterviewsInterviews with patients, physicians and general practitioners (GPs) to define patients' decisional needs. | Other | 1.Patients, 2.Clinicians |
| Treatmentchoice Decisional ToolPatients and physicians navigate through Treatmentchoice Decisional Tool and think aloud while running the tool | Other | 1.Patients, 2.Clinicians |
| QuestionnairesPatients and physicians fill out questionnaires on the usual care, Delphi study | Other | 1.Patients, 2.Clinicians |
| Interviews with stakeholdersInterviews with stakeholders (patients, clinicians, nurses, GP's, patient organizations, insurance companies) to determine the barriers and facilitators to the implementation of shared decision making and the decision aid. | Other | 3.Other involved organizations |
Primary outcome
Patient's decisional needs to make a decision about their treatment
Time frame: up to 1 year
Patients' decisional needs (development phase):semi-structured interviews with patients about their medical history, their experience with the treatment, the decision about their treatment, and what information the patients need to make an informed decision
Comprehensibility of the decision aid too
Time frame: up to 1 year
Quantitative research using the Unified Theory of Acceptance and Use of Technology (UTAUT Venkatesh et al. 2013). This questionnaire. (5-Likert) measure how patients and clinicians perceived its utility, effectiveness and efficiency for shared decision-making, as well as their satisfaction with the decision aid.
Usability of the decision aid too
Time frame: up to 1 year
Quantitative research using a questionnaire based on the International Standard ISO-9242-11. This questionnaire (5-Likert) measure to what extent the decision aid is easy to use.
Decisional conflict (patients, evaluation phase)
Time frame: 2 weeks after diagnosis
Decisional conflict will be assessed using the DCS (Decisional conflict scale): change in DCS between baseline group (usual care) and intervention group (use of the aid tool)
Control Preference Scale (patients; evaluation phase)
Time frame: 2 weeks after diagnosis
Patient's preference to participate in medical decisions will be assessed using the 5-item Control Preference Scale (CPS):change in CPS between baseline group (usual care) and intervention group (use of the aid tool)
Perception shared decision-making (patients; evaluation phase)
Time frame: 2 weeks after diagnosis
Patient's perception of the shared decision-making process will be assessed using the (shared decision making) SDM-Q9 instrument for patients: change in SDM between baseline group (usual care) and the intervention group (use of the aid tool)
Perception shared decision-making (doctors; evaluation phase)
Time frame: 2 weeks after diagnosis
Doctor's perception of the shared decision-making process will be assessed using the SDM-Q9 instrument for professionals: change in SDM between baseline group (usual care) and the intervention group (use of the aid tool)]]
4 secondary outcomes
Patients' views on the current decision-making process
Time frame: upto 1 year
Patients' satisfaction with decision aid (Treatmentchoice)
Time frame: upto 1 year
Patients' intention to use and recommend Treatmentchoice to others
Time frame: upto 1 year
Insights into the value clarification process of prostate cancer patients
Time frame: an average of 2 year
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 30 Nov 2020.
- Individual participant dataSharing planned: No
Related trials for Prostate Cancer
Enrolling by invitationObservational study
Natural History Study of Early Life Exposures in Agriculture (ELEA)
Prostate Cancer, Leukemia
Active, not recruitingPhase 3
Stereotactic Body Radiation Therapy or Intensity-Modulated Radiation Therapy in Treating Patients With Stage IIA-B Prostate Cancer
Stage II Prostate Adenocarcinoma AJCC v7
RecruitingPhase 2
Psilocybin-Assisted Psychotherapy in Cancer Patients With Adjustment Disorder
Adjustment Disorder, Adjustment Disorder With Anxious Mood
RecruitingPhase 1
Pilot Study for Detection of PSMA-Low CRPC-NE Tumors With Fluciclovine PET/CT
Advanced Prostate Cancer, Metastatic Prostate Cancer
RecruitingPhase 1
Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01)
Prostate Cancer, Metastatic Castration-resistant Prostate Cancer
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Philippe Lambin, MD,PhD principal investigator
Maastro Clinic, The Netherlands
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Interviews, Treatmentchoice Decisional Tool and Questionnaires in people with Prostate Cancer, run by Maastricht Radiation Oncology at 1 site in Netherlands.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 13 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 30 Nov 2020. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Netherlands. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Patient's decisional needs to make a decision about their treatment (time frame: up to 1 year). The study lists 7 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 30 Nov 2020.